These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 8816746)

  • 1. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.
    Silva AM; Lee AY; Gulnik SV; Maier P; Collins J; Bhat TN; Collins PJ; Cachau RE; Luker KE; Gluzman IY; Francis SE; Oksman A; Goldberg DE; Erickson JW
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10034-9. PubMed ID: 8816746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
    Rumsh LD; Mikhaĭlova AG; Mikhura IV; Prudchenko IA; Chikin LD; Mikhaleva II; Kaliberda EN; Dergousova NI; Mel'nikov EE; Formanovskiĭ AA
    Bioorg Khim; 2008; 34(6):739-46. PubMed ID: 19088746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
    Carroll CD; Patel H; Johnson TO; Guo T; Orlowski M; He ZM; Cavallaro CL; Guo J; Oksman A; Gluzman IY; Connelly J; Chelsky D; Goldberg DE; Dolle RE
    Bioorg Med Chem Lett; 1998 Sep; 8(17):2315-20. PubMed ID: 9873534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum.
    Mohapatra SC; Tiwari HK; Singla M; Rathi B; Sharma A; Mahiya K; Kumar M; Sinha S; Chauhan SS
    J Biol Inorg Chem; 2010 Mar; 15(3):373-85. PubMed ID: 19946719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoglobin-degrading, aspartic proteases of blood-feeding parasites: substrate specificity revealed by homology models.
    Brinkworth RI; Prociv P; Loukas A; Brindley PJ
    J Biol Chem; 2001 Oct; 276(42):38844-51. PubMed ID: 11495896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
    Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
    Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum.
    Asojo OA; Gulnik SV; Afonina E; Yu B; Ellman JA; Haque TS; Silva AM
    J Mol Biol; 2003 Mar; 327(1):173-81. PubMed ID: 12614616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor.
    Nezami A; Kimura T; Hidaka K; Kiso A; Liu J; Kiso Y; Goldberg DE; Freire E
    Biochemistry; 2003 Jul; 42(28):8459-64. PubMed ID: 12859191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
    Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
    J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.
    Hodder AN; Sleebs BE; Czabotar PE; Gazdik M; Xu Y; O'Neill MT; Lopaticki S; Nebl T; Triglia T; Smith BJ; Lowes K; Boddey JA; Cowman AF
    Nat Struct Mol Biol; 2015 Aug; 22(8):590-6. PubMed ID: 26214367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
    Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
    Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole.
    Luker KE; Francis SE; Gluzman IY; Goldberg DE
    Mol Biochem Parasitol; 1996 Jul; 79(1):71-8. PubMed ID: 8844673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structures of the free and inhibited forms of plasmepsin I (PMI) from Plasmodium falciparum.
    Bhaumik P; Horimoto Y; Xiao H; Miura T; Hidaka K; Kiso Y; Wlodawer A; Yada RY; Gustchina A
    J Struct Biol; 2011 Jul; 175(1):73-84. PubMed ID: 21521654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The aspartic proteinase from the rodent parasite Plasmodium berghei as a potential model for plasmepsins from the human malaria parasite, Plasmodium falciparum.
    Humphreys MJ; Moon RP; Klinder A; Fowler SD; Rupp K; Bur D; Ridley RG; Berry C
    FEBS Lett; 1999 Dec; 463(1-2):43-8. PubMed ID: 10601635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite.
    Westling J; Yowell CA; Majer P; Erickson JW; Dame JB; Dunn BM
    Exp Parasitol; 1997 Nov; 87(3):185-93. PubMed ID: 9371083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A; Luque I; Kimura T; Kiso Y; Freire E
    Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
    Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
    Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
    Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
    Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartic proteinases from the human malaria parasite Plasmodium falciparum.
    Berry C; Dame JB; Dunn BM; Kay J
    Adv Exp Med Biol; 1995; 362():511-8. PubMed ID: 8540365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.